Generic name: Voxelotor 500mg
Dosage form: tablet, film coated
Medically reviewed by Drugs.com. Last updated on Jul 30, 2020.
Recommended Dosage for Sickle Cell Disease
The recommended dosage of OXBRYTA is 1,500 mg taken orally once daily with or without food. If a dose is missed, continue dosing on the day following the missed dose.
Patients should swallow OXBRYTA tablets whole. Do not cut, crush, or chew the tablets.
OXBRYTA may be given with or without hydroxyurea.
Recommended Dosage for Hepatic Impairment
The recommended dosage of OXBRYTA in patients with severe hepatic impairment (Child Pugh C) is 1,000 mg taken once daily with or without food. No dosage adjustment of OXBRYTA is required for patients with mild or moderate hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Recommended Dosage of OXBRYTA When Used with Concomitant Moderate or Strong Inducers, Strong Inhibitors of CYP3A4, or Fluconazole
Avoid concomitant use of strong or moderate CYP3A4 inducers, strong CYP3A4 inhibitors, or fluconazole with OXBRYTA [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. If concomitant use of strong or moderate CYP3A4 inducers, strong CYP3A4 inhibitors, or fluconazole is unavoidable, adjust the OXBRYTA dosage as recommended in Table 1.
|Concomitant Medication||Recommended OXBRYTA Dosage|
|Strong CYP3A4 inhibitors or fluconazole||1,000 mg once daily|
|Strong or moderate CYP3A4 inducers||2,500 mg once daily|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Oxbryta (voxelotor)
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 3 Reviews
- Drug class: miscellaneous uncategorized agents
- FDA Approval History